M&A Deal Summary |
|
---|---|
Date | 2023-05-22 |
Target | VectivBio |
Sector | Life Science |
Buyer(s) | Ironwood Pharmaceuticals |
Deal Type | Add-on Acquisition |
Deal Value | 1.0B USD |
Advisor(s) | Centerview Partners BofA Securities (Financial) Cooley Homburger (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1998 |
Sector | Life Science |
Employees | 267 |
Revenue | 443M USD (2023) |
Ironwood Pharmaceuticals is a healthcare company, that focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. Ironwood Pharmaceuticals was founded in 1998 and is based in Boston, Massachusetts.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Add-on Acquisition) | 1 of 1 |
Country (Switzerland) | 1 of 1 |
Year (2023) | 1 of 1 |
Size (of disclosed) | 1 of 1 |